Last reviewed 2026-05-19 · How we verify

CICLOSIDOMINE

Phase 2 active Small molecule ✓ Verified May 2026

CICLOSIDOMINE is a ciclosidomine drug. It is currently in Phase 2 development.

Ciclosidomine is thought to work by interacting with a specific molecular target, although the exact mechanism is not well understood.

CICLOSIDOMINE is a small molecule with the synonyms CICLOSIDOMINA, CICLOSIDOMINE, PR-G 138-CL FREE BASE, and PR-G-138-CL FREE BASE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CICLOSIDOMINE
Drug class	ciclosidomine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine ciclosidomine as a key that fits into a lock on a cell's surface. When it binds to this lock, it can trigger a series of events that help to treat a particular disease or condition. However, the details of how ciclosidomine works are still being studied and are not yet fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CICLOSIDOMINE CI brief — competitive landscape report
CICLOSIDOMINE updates RSS · CI watch RSS

Frequently asked questions about CICLOSIDOMINE

What is CICLOSIDOMINE?

CICLOSIDOMINE is a ciclosidomine drug.

How does CICLOSIDOMINE work?

Ciclosidomine is thought to work by interacting with a specific molecular target, although the exact mechanism is not well understood.

What drug class is CICLOSIDOMINE in?

CICLOSIDOMINE belongs to the ciclosidomine class. See all ciclosidomine drugs at /class/ciclosidomine.

What development phase is CICLOSIDOMINE in?

CICLOSIDOMINE is in Phase 2.

Drug class: All ciclosidomine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing